1-20 of 49144 Search Results for

mutations

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5839.
Published: 15 June 2022
...Rong Bu; Abdul K. Siraj; Tariq Masoodi; Sandeep Kumar Parvathareddy; Kaleem Iqbal; Allianah D. Benito; Sarah Siraj; Nabil Siraj; Maha Al Rasheed; Saeeda O. Ahmed; Wael AL-Haqaw; Maria Angelita Sabido; Mark Ranier Diaz; Padmanaban Annaiyappanaidu; Khawla S. Al-Kuraya Mutation-induced activation...
Journal Articles
Cancer Res (2022) 82 (13): 2361–2377.
Published: 05 July 2022
...Dan Huang; Cristel V. Camacho; Sara Martire; Anusha Nagari; Rohit Setlem; Xuan Gong; Andrea D. Edwards; Shu-Ping Chiu; Laura A. Banaszynski; W. Lee Kraus Recent studies have identified cancer-associated mutations in histone genes that lead to the expression of mutant versions of core histones...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5833.
Published: 15 June 2022
... to arise from the distal end of the fallopian tube. About 96% of HGSC cases were found to contain mutations in TP53 and missense mutation was the most frequent type. It is known that TP53 mutation is an early event occurred in HGSC and may drive tumorigenesis. Different TP53 mutations have been reported...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5838.
Published: 15 June 2022
...shun xu; Zhichao Fu Background: The epidermal growth factor receptor (EGFR) is one of the most commonly altered genes in non-small cell lung cancer(NSCLC). Of these, insertion mutation in 20 exon (Ex20ins) of the EGFR occurs less frequently. In comparison with the common EGFR mutations (19Del/L858R...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5840.
Published: 15 June 2022
...Xinyu Hong; Ximeng Zhao; Zeshang Guo; Xiaochen Yang; Bella Guo; Xiang Zhang; Tonghui Ma Backgrounds:TP53 germline mutation is well known to be the cause of Li-Fraumeni syndrome (LFS), a rare autosomal dominant cancer syndrome, characterized by predisposition of breast cancer, soft tissue carcinoma...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5842.
Published: 15 June 2022
... younger than 50. Due to fragile economic situation in the middle east and lack of awareness, BC women are characterized by late diagnosis and thus, there is an urgent need for a cheap early prognostic tool. BC progression involves several genetic mutations via activating oncogenes or disrupting...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1215.
Published: 15 June 2022
..., such as cancer vaccines, rely on neoantigen prediction to identify sequences that can activate T cells to recognize and destroy the tumor. The majority of cancer vaccine trials have utilized neoantigens derived from missense mutations and small insertions and deletions. However, other mutation types could...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3259.
Published: 15 June 2022
...Hidefumi Kasuga; Yuki Kataoka; Fuyuki Yamamoto; Takashi Mizutani; Shingo Tsuji; Sakiho Tanaka; Shinji Mizuarai Background: Common mutations (exon 19 deletion; ex19del or L858R point mutation; L858R) of the epidermal growth factor receptor (EGFR) are found in patients with non-small cell lung cancer...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3261.
Published: 15 June 2022
...Paul G. Pearson; Anjali Pandey; Bruce Roth; Tracy Saxton; Daniel J. Estes; Ravi Trivedi; Himanshu Agrawal; Gurulingappa Hallur; Ishtiyaque Ahmad; Helen Jenkins; Brion W. Murray Exon 20 insertion mutations (Ex20ins) are the 3rd most common type of EGFR oncogenic mutation in lung cancer patients...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1181.
Published: 15 June 2022
... type. Co-occurring mutations may affect tumor response, supported by previous studies demonstrating that NF1 mutations confer resistance to HRAS inhibition by the FTI tipifarnib in thyroid cancer mouse models. We aimed to determine if PI3K pathway activating mutations altered responses to targeted...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1388.
Published: 15 June 2022
... and presentation machinery (APM) have not been extensively studied. Using a harmonized dataset of six clinical trials of patients with melanoma treated with ICB, whole-exome sequencing (WES, n= 244) and RNA sequencing (RNAseq, n= 426) data from untreated tumor samples were assessed to identify mutations in genes...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 6257.
Published: 15 June 2022
... for 48h followed by Alv for 24h). Cell viability was determined using CellTiter-Glo (CTG) and Annexin-V apoptosis assays. MCL-1 dependency of MDS samples was assessed using MS1 peptide-based assay. Recurrent myeloid neoplasia mutations in 67 genes were assessed in BM mononuclear cells using NGS panel deep...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 750.
Published: 15 June 2022
... serous carcinomas (USC) comprise 10-15% of all uterine cancers, but are responsible for approximately 40% of all deaths due to the disease. African American women have the highest incidence of and mortality from USC of any racial or ethnic group. Assessment of racial differences in driver mutation...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): LB134.
Published: 15 June 2022
... Dowgielewicz3; Elisa Rumi; Daniela Pietra; Ilaria Carola Casetti; Steffen Koschmieder5; Sandeep Gurbuxani; Rebekka K. Schneider; Scott A. Oakes; Shannon E. Elf Approximately 20% of patients with myeloproliferative neoplasms (MPN) harbor mutations in the gene calreticulin (CALR). 80% of CALR mutations...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): PL03-02.
Published: 15 June 2022
.... The components of inherited lung cancer risk, particularly in nonsmokers, are not fully understood, but there appear to be variations in lung adenocarcinoma mutations in distinct ancestry groups, which may be related to inherited factors. In particular, the frequency of somatic EGFR and KRAS mutations in lung...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1041.
Published: 15 June 2022
... of cancer cells and also acting as an immune checkpoint molecule to suppress tumor immunity. HBI-2376 is an orally bioavailable selective SHP2 inhibitor that is being developed for the treatment of solid tumors harboring KRAS or EGFR mutations, such as non-small cell lung cancer (NSCLC) and colorectal...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1783.
Published: 15 June 2022
...Marwa Taya; Keren Merenbakh-Lamin; Tami Rubinek; Ido Wolf Background: Endocrine therapy is the mainstay treatment for estrogen receptor-α (ER) positive breast cancer (BC) patients. However, all metastatic BC patients develop resistance, which in nearly 40% of patients is due to activating mutations...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): CT007.
Published: 15 June 2022
..., prostate or pancreatic cancer bearing germline or somatic BRCA1/2, PALB2 or RAD51C/D mutations received AZD5305 QD PO until disease progression. ECOG PS 0-2 and Hb ≥9.0 g/dL were required. Prior PARPi and platinum therapy were permitted. The primary objective was safety; secondary objectives included...
Journal Articles
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 449.
Published: 15 June 2022
... processes. Approximately 19% of lung adenocarcinoma (LUAD) tumors have a mutation in KEAP1. Clinically, KEAP1-mutated LUAD has poor prognosis, and there is need for rapid and accurate patient genotyping to inform treatment decisions. Here, we describe machine learning (ML) models that can predict KEAP1...